HBM (HKG:2142) plans to repurchase up to HK$200 million of shares under a buyback mandate, according to a Thursday filing with the Hong Kong bourse.
The drug company has so far allocated HK$240 million for share buybacks in 2025 on a year-to-date basis, the filing said.
Shares surged 12% during Friday's afternoon trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.